Get the Stockscreener App
196.63
0.18%
0.36
After Hours:
196.63
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Quest Diagnostics Inc stock is traded at $196.63, with a volume of 701.27K.
It is up +0.18% in the last 24 hours and up +0.57% over the past month.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
See More
Previous Close:
$196.27
Open:
$195.91
24h Volume:
701.27K
Relative Volume:
0.70
Market Cap:
$21.77B
Revenue:
$11.28B
Net Income/Loss:
$1.07B
P/E Ratio:
21.69
EPS:
9.0657
Net Cash Flow:
$1.33B
1W Performance:
+0.16%
1M Performance:
+0.57%
6M Performance:
+9.08%
1Y Performance:
+13.16%
1-Day Range:
$195.61
$198.00
1-Week Range:
$194.46
$209.79
52-Week Range:
$164.65
$213.50
Quest Diagnostics Inc Stock (DGX) Company Profile
Name
Quest Diagnostics Inc
Sector
Industry
Phone
(973) 520-2700
Address
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
196.63 | 21.73B | 11.28B | 1.07B | 1.33B | 9.0657 |
TMO
Thermo Fisher Scientific Inc
|
468.04 | 174.55B | 45.20B | 6.88B | 6.75B | 18.19 |
DHR
Danaher Corp
|
180.62 | 125.45B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
574.95 | 44.95B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
115.62 | 32.65B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
299.79 | 30.42B | 3.17B | 642.63M | 516.49M | 10.77 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-25-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-02-25 | Initiated | Redburn Atlantic | Buy |
| Mar-04-25 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-17-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | Jefferies | Buy |
| Oct-23-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Aug-28-24 | Resumed | Evercore ISI | In-line |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Feb-07-24 | Upgrade | Jefferies | Hold → Buy |
| Jan-03-24 | Initiated | Barclays | Equal Weight |
| Dec-12-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-29-23 | Initiated | Piper Sandler | Neutral |
| May-02-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-03-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-23-23 | Initiated | Evercore ISI | In-line |
| Nov-17-22 | Downgrade | Citigroup | Neutral → Sell |
| Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-04-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-22 | Downgrade | UBS | Buy → Neutral |
| Feb-02-22 | Downgrade | Jefferies | Buy → Hold |
| Jan-28-22 | Downgrade | Deutsche Bank | Buy → Hold |
| May-04-21 | Upgrade | UBS | Neutral → Buy |
| Mar-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-21-20 | Upgrade | Argus | Hold → Buy |
| Jul-29-20 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jul-14-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-09-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jun-02-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-28-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-27-20 | Upgrade | Citigroup | Neutral → Buy |
| Apr-27-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Mar-27-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jul-15-19 | Downgrade | Goldman | Neutral → Sell |
| Apr-02-19 | Upgrade | Jefferies | Hold → Buy |
| Mar-18-19 | Resumed | Credit Suisse | Neutral |
| Jan-31-19 | Downgrade | Argus | Buy → Hold |
| Jan-17-19 | Initiated | UBS | Neutral |
| Jan-03-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Dec-03-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Nov-30-18 | Downgrade | Goldman | Buy → Neutral |
View All
Quest Diagnostics Inc Stock (DGX) Latest News
Quest Diagnostics prices $500M debt deal ahead of June note maturity - Stock Titan
Quest Diagnostics Inc files for senior notes, size not disclosed - marketscreener.com
[Form 4] QUEST DIAGNOSTICS INC Insider Trading Activity - Stock Titan
Quest Diagnostics (DGX) SVP reports 49-share dividend reinvestment - Stock Titan
Quest Diagnostics (NYSE: DGX) director acquires shares through dividend reinvestment - Stock Titan
Dividend plan boosts Quest Diagnostics (NYSE: DGX) director stake - Stock Titan
Quest Diagnostics (DGX) director boosts holdings with small dividend reinvestment - Stock Titan
Quest Diagnostics (NYSE: DGX) SVP reports small 39-share acquisition - Stock Titan
Quest Diagnostics (NYSE: DGX) SVP adds 37 shares through dividend reinvestment - Stock Titan
Quest Diagnostics Inc. stock underperforms Friday when compared to competitors - MarketWatch
Quest Diagnostics: Good Q1, Solid Business, Steady Share Price Upside Likely (NYSE:DGX) - Seeking Alpha
Copeland Capital Management LLC Cuts Stake in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Incorporated $DGX Stock Holdings Decreased by Cwm LLC - MarketBeat
These Companies Are Raising Guidance This Earnings Season - TradingView
Quest Diagnostics Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG), Quest Diagnostics (DGX) and Merck & Company (MRK) - The Globe and Mail
Zurcher Kantonalbank Zurich Cantonalbank Has $14.02 Million Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics (NYSE: DGX) boosts Q1 2026 earnings on 11% volume growth - Stock Titan
Quest Diagnostics deal helps push Secaucus office tower past 75% occupancy - Yahoo Finance
Quest Diagnostics Stock Gains 5% After Q1 Earnings Exceed Analyst Expectations - TIKR.com
Quest Diagnostics (NYSE:DGX) Price Target Raised to $229.00 - MarketBeat
Quest Diagnostics (NYSE:DGX) Stock Price Expected to Rise, Barclays Analyst Says - MarketBeat
These Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Earnings - Benzinga
Here's Why Quest Diagnostics (DGX) is a Strong Momentum Stock - Yahoo Finance
Truist Financial Forecasts Strong Price Appreciation for Quest Diagnostics (NYSE:DGX) Stock - MarketBeat
Quest Diagnostics Incorporated (NYSE:DGX) Q1 2026 Earnings Call Transcript - Insider Monkey
Evercore ISI Adjusts Price Target on Quest Diagnostics to $225 From $210, Maintains In Line Rating - marketscreener.com
Jefferies Adjusts Price Target on Quest Diagnostics to $225 From $220, Maintains Buy Rating - marketscreener.com
Barclays Adjusts Price Target on Quest Diagnostics to $230 From $225, Maintains Overweight Rating - marketscreener.com
Baird Adjusts Price Target on Quest Diagnostics to $229 From $224, Maintains Neutral Rating - marketscreener.com
Quest Diagnostics Inc (DGX) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance - GuruFocus
Quest Diagnostics Inc (DGX) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Raised ... By GuruFocus - Investing.com Canada
Quest Diagnostics rises after raising 2026 outlook following Q1 beat - MSN
How The Investment Story For Quest Diagnostics (DGX) Is Quietly Shifting Now - Yahoo Finance
Is Quest Diagnostics Inc (DGX) Overvalued After 4.5% Rally? GF V - GuruFocus
Quest Diagnostics Lifts Outlook On Strong Earnings Call - TipRanks
Is Quest Diagnostics Inc (DGX) Overvalued After 4.5% Rally? GF Value Says Overvalued - GuruFocus
Quest Diagnostics Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Jefferies Raises Quest Diagnostics Price Target to $225 From $220 - marketscreener.com
Why Is Quest Diagnostics Stock Soaring Tuesday?Quest Diagnostics (NYSE:DGX) - Benzinga
Quest Diagnostics raises guidance following earnings beat - marketscreener.com
Quest Diagnostics Incorporated Q1 2026 Earnings Call Summary - Yahoo Finance
Quest Diagnostics raises 2026 forecast, CEO highlights broad-based growth - marketscreener.com
Valmont Industries posts upbeat Q1 results, joins UnitedHealth Group, Quest Diagnostics and other big stocks moving higher on Tuesday - MSN
Quest Diagnostics Q1 Earnings Call Highlights - Yahoo Finance
Valmont Industries Posts Upbeat Q1 Results, Joins UnitedHealth Group, Quest Diagnostics And Other Big Sto - Benzinga
Quest Diagnostics Q1 2026 Earnings Call: Complete TranscriptQuest Diagnostics (NYSE:DGX) - Benzinga
Quest Diagnostics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Quest Diagnostics' Q1 Earnings & Revenues Top Estimates, Stock Up - Yahoo Finance
Q1 2026 Quest Diagnostics Inc Earnings Call Transcript - GuruFocus
Quest Diagnostics Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Quest Diagnostics Inc Stock (DGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):